Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of market conditions, including competition and the need for ongoing monitoring, which significantly impacted patient starts [3]. - The lawsuit further asserts that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the unmet medical needs, particularly among first-line patients [3]. Financial Impact - Following the announcement of its fourth-quarter financial results for fiscal year 2024 on February 26, 2025, Geron reported that Rytelo's growth had stagnated, attributing this to seasonality, competition, and lack of awareness [4]. - The announcement led to a decline of over 32% in Geron's stock price, reflecting the negative market reaction to the news [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Geron [2]. - The complaint alleges that Geron and its executives made false and misleading statements regarding the company's drug Rytelo, downplaying risks associated with its monitoring requirements and competition [4]. - Investors who suffered losses exceeding $100,000 in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Financial Performance and Stock Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had flattened due to seasonality, competition, and lack of awareness [5]. - Following the announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [6].

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between June 7, 2024, and February 25, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the launch and growth potential of its drug Rytelo (imetelstat), downplaying risks associated with monitoring requirements and competition [2] - Following the announcement of Geron's fourth quarter financial results for fiscal 2024 on February 26, 2025, which revealed that Rytelo's growth had flattened, the company's stock price dropped significantly from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's drug Rytelo and its market performance [3][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Geron to contact them, highlighting a deadline of May 12, 2025, to seek the role of lead plaintiff in a federal securities class action [1][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Group 2: Allegations Against Geron - The complaint against Geron alleges that the company and its executives made false and misleading statements regarding their ability to meet market needs and execute their commercial plans, while downplaying risks associated with Rytelo [3]. - Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring requirements [4]. Group 3: Stock Price Impact - Following the announcement of Rytelo's diminished growth, Geron's stock price fell from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [5].

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=137097&from=4CLASS PERIOD: June 7, 2024 to ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Geron Corporation securities between June 7, 2024, and February 25, 2025, alleging misleading statements regarding the company's revenue outlook and growth potential [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Geron Corporation made false and misleading statements about its projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is alleged that Geron's reports on the launch success of Rytelo, a telomerase inhibitor, did not accurately reflect the challenges faced in the market, including competition and the need for ongoing monitoring [5]. - The lawsuit indicates that when the true situation became known, investors suffered damages due to the misleading information provided by Geron [5]. Group 2: Class Action Participation - Investors who purchased Geron securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must file their motion by May 12, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the performance and market expectations of its drug Rytelo (imetelstat) between June 7, 2024, and February 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were negatively impacted by the defendants' misleading statements regarding Rytelo's launch and growth potential [1][2]. - Defendants allegedly downplayed risks associated with Rytelo, including the burden of weekly monitoring and competition, while expressing confidence in the drug's market potential [2]. - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024, which revealed stagnant growth for Rytelo, the company's stock price plummeted approximately 32.07%, from $2.37 to $1.61 per share in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs for class members, and they may be entitled to compensation without financial obligation [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Geron Corp (NASDAQ: GERN ) is a venerable, long-in-development-hell biotech working on the commercialization and development of the lone telomerase inhibitor approved for any indication. The year 2024 saw the first sales of their agent Rytelo in the space of lower-riskI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do y ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about its revenue outlook and growth potential [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron provided false and misleading information to investors, creating an overly optimistic view of the projected revenue and growth related to the launch of Rytelo [2]. - It is alleged that Geron did not disclose that Rytelo lacked necessary patient awareness, which hindered the company's ability to meet the claimed significant unmet need for the drug [2]. Group 2: Investor Participation - Shareholders who purchased Geron's securities between June 7, 2024, and February 25, 2025, are encouraged to contact the DJS Law Group to participate in the class action lawsuit before May 12, 2025 [1][3].